Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
3.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
4.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol
; 20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197267
5.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642080
6.
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031762
7.
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Eur J Haematol
; 110(5): 564-570, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726221
8.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
9.
Circular RNAs in acute myeloid leukemia.
Mol Cancer
; 20(1): 149, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794438
10.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970288
11.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
12.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(10): 1317-1330, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32866432
13.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Br J Haematol
; 186(4): 549-560, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31124580
14.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Blood
; 130(5): 597-605, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550039
15.
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Future Oncol
; 15(13): 1411-1428, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30816809
16.
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Br J Haematol
; 180(1): 41-51, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076150
17.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817190
18.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
Blood
; 125(3): 443-8, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395429
19.
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
Biol Blood Marrow Transplant
; 22(5): 869-78, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827660
20.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer
; 122(21): 3327-3335, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433944